Forbes J M & Co. LLP Has $600,000 Stock Holdings in Pfizer Inc. (NYSE:PFE)

Forbes J M & Co. LLP cut its position in shares of Pfizer Inc. (NYSE:PFE) by 7.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 20,742 shares of the biopharmaceutical company’s stock after selling 1,591 shares during the quarter. Forbes J M & Co. LLP’s holdings in Pfizer were worth $600,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Hennion & Walsh Asset Management Inc. lifted its stake in Pfizer by 16.0% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 41,275 shares of the biopharmaceutical company’s stock worth $1,145,000 after purchasing an additional 5,682 shares during the period. Diversified Trust Co raised its stake in shares of Pfizer by 9.8% in the first quarter. Diversified Trust Co now owns 115,159 shares of the biopharmaceutical company’s stock valued at $3,196,000 after acquiring an additional 10,258 shares during the last quarter. Claro Advisors LLC raised its stake in shares of Pfizer by 1.2% in the first quarter. Claro Advisors LLC now owns 39,528 shares of the biopharmaceutical company’s stock valued at $1,097,000 after acquiring an additional 456 shares during the last quarter. Park Place Capital Corp raised its stake in shares of Pfizer by 4.2% in the first quarter. Park Place Capital Corp now owns 18,570 shares of the biopharmaceutical company’s stock valued at $515,000 after acquiring an additional 756 shares during the last quarter. Finally, Eagle Capital Management LLC raised its stake in shares of Pfizer by 0.8% in the first quarter. Eagle Capital Management LLC now owns 126,004 shares of the biopharmaceutical company’s stock valued at $3,497,000 after acquiring an additional 1,056 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on PFE. Barclays lifted their target price on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Sanford C. Bernstein initiated coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price for the company. Citigroup initiated coverage on shares of Pfizer in a research report on Friday. They issued a “neutral” rating and a $30.00 price objective for the company. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Finally, UBS Group boosted their price objective on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Eight investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $33.58.

Pfizer Trading Up 1.6 %

PFE traded up $0.45 during trading on Monday, reaching $28.90. 7,258,425 shares of the company’s stock were exchanged, compared to its average volume of 36,707,230. The company’s fifty day moving average price is $29.08 and its 200-day moving average price is $28.53. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $31.54. The firm has a market capitalization of $163.76 billion, a PE ratio of -474.17, a P/E/G ratio of 1.01 and a beta of 0.67.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. During the same quarter in the previous year, the business earned $0.67 EPS. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. As a group, equities analysts forecast that Pfizer Inc. will post 2.67 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 5.81%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is -2,800.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.